Ophthopedia
banner
ophthalmology.bsky.social
Ophthopedia
@ophthalmology.bsky.social
Latest updates on publications and news from #ophthalmology and #visionscience. Curated by @rohanbir.bsky.social.

Let the #OphthoSky begin! :)
Pinned
New to @bsky.app and looking for your colleagues and friends from the world of #ophthalmology and #visionsciences.

They are here....
Ophthopedia Update: Weekly Journal Update — December 3, 2025: Rates of corneal transplants after glaucoma surgery, predicting AMD genetics from fundus images, OCT- vs photography-based model for detecting glaucoma, diversity microbiota in congenital nasolacrimal duct… #Ophthalmology #News
Weekly Journal Update — December 3, 2025
Rates of corneal transplants after glaucoma surgery, predicting AMD genetics from fundus images, OCT- vs photography-based model for detecting glaucoma, diversity microbiota in congenital nasolacrimal duct obstruction, blue light–filtering IOLs and exudative AMD.
dlvr.it
December 3, 2025 at 8:24 PM
Ophthopedia Update: FDA approve generic version of Restasis: The FDA approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, a generic equivalent of Restasis, for the treatment of dry eye disease, according to a company press release.
The topical… #ophthalmology #eye #eyenews
FDA approve generic version of Restasis
The FDA approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, a generic equivalent of Restasis, for the treatment of dry eye disease, according to a company press release. The topical immunomodulator is a sterile, preservative-free formulation supplied in single-use vials. It is indicated for increasing tear production in patients with ocular inflammation. The most common adverse event among patients treated with cyclosporine ophthalmic emulsion 0.05% was ocular burning, Amneal said in the release. “Dry eye disease affects millions of adults in the United States and can
dlvr.it
December 3, 2025 at 7:53 PM
Ophthopedia Update: FDA approve generic version of Restasis: The FDA approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, a generic equivalent of Restasis, for the treatment of dry eye disease, according to a company press release.
The topical immunomodulator is a sterile,…
FDA approve generic version of Restasis
The FDA approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, a generic equivalent of Restasis, for the treatment of dry eye disease, according to a company press release. The topical immunomodulator is a sterile, preservative-free formulation supplied in single-use vials. It is indicated for increasing tear production in patients with ocular inflammation. The most common adverse event among patients treated with cyclosporine ophthalmic emulsion 0.05% was ocular burning, Amneal said in the release. “Dry eye disease affects millions of adults in the United States and can
dlvr.it
December 3, 2025 at 7:49 PM
Ophthopedia Update: Differentiating keratoconus from impostors key to diagnosis: BOSTON — Differentiating keratoconus from potential impostor conditions is a key factor in making a timely diagnosis for optimal outcomes, according to a presenter.
“It’s really important to know whether it’s truly…
Differentiating keratoconus from impostors key to diagnosis
BOSTON — Differentiating keratoconus from potential impostor conditions is a key factor in making a timely diagnosis for optimal outcomes, according to a presenter. “It’s really important to know whether it’s truly keratoconus or one of its impostors because the right diagnosis guides everything that follows,” Michelle Chung, OD, FAAO, FSLS, of Princeton Optometry, New Jersey, told Healio at Academy 2025. “Some of these conditions are progressive and need to be treated early to prevent vision loss, or others are a little more stable and can be managed differently.” {{VIDEO}} Key features to look
dlvr.it
December 3, 2025 at 6:28 PM
Ophthopedia Update: Association of polymorphisms in 17 loci with primary open-angle glaucoma in Chinese and Japanese: Purpose

To evaluate the associations of single-nucleotide polymorphisms (SNPs) in 17 loci with primary open-angle glaucoma (POAG) and subtypes… #Ophthalmology #Ophthotwitter #BJO
Association of polymorphisms in 17 loci with primary open-angle glaucoma in Chinese and Japanese
Purpose To evaluate the associations of single-nucleotide polymorphisms (SNPs) in 17 loci with primary open-angle glaucoma (POAG) and subtypes in Chinese and Japanese.Methods 17 SNPs in 17 genes, selected from a recent genome-wide association study, were genotyped in a Hong Kong Chinese cohort of 1093 POAG patients, including 557 high-tension glaucoma (HTG) and 536 normal-tension glaucoma (NTG) patients, and 584 controls. Seven SNPs showing association in the Hong Kong cohort were genotyped in a Shantou Chinese cohort of 155 POAG patients and 380 controls and an Osaka Japanese cohort of 254 POAG patients and 207 controls. The SNP-disease association of individual and pooled cohorts was analysed.Results In combined Chinese and Japanese subjects, three SNPs were significantly associated with POAG: AFAP1 rs938604 (Pmeta =6.40x10–5, OR=0.70), FNDC3B rs62283813 (Pmeta =0.0050, OR=1.24) and GAS7 rs9913911 (Pmeta =0.0060, OR=1.19). In subgroup analysis, these three SNPs showed stronger association with HTG: AFAP1 rs938604 (Pmeta =8.00x10–6, OR=0.59), FNDC3B rs62283813 (Pmeta =6.00x10–7, OR=1.55) and GAS7 rs9913911 (Pmeta =0.0040, OR=1.24). In addition, SPRED2 rs4414666 (Pmeta =8.00x10–4, OR=1.29) was also significantly associated with HTG. No SNP showed a significant association with NTG.Conclusions This study confirms AFAP1 rs938604, FNDC3B rs62283813, GAS7 rs9913911 and SPRED2 rs4414666 as HTG-specific loci in Chinese and Japanese populations. These findings provide new insights into the genetic architecture of POAG, highlighting distinct molecular mechanisms between HTG and NTG subtypes.
dlvr.it
December 3, 2025 at 5:43 PM
Ophthopedia Update: Incidence and factors associated with incident cataract surgery in a rural population in the Indian state of Andhra Pradesh: findings from the Andhra Pradesh Eye Disease Study III: Purpose

The Andhra Pradesh Eye Disease Study III (APEDS III)… #Ophthalmology #Ophthotwitter #BJO
Incidence and factors associated with incident cataract surgery in a rural population in the Indian state of Andhra Pradesh: findings from the Andhra Pradesh Eye Disease Study III
Purpose The Andhra Pradesh Eye Disease Study III (APEDS III) is a 15-year follow-up of participants examined in APEDS I. The aim of the study was to report the 15-year incidence of cataract surgery and its associated factors among rural populations.Methods This population-based longitudinal cohort study was conducted in three rural regions of the Indian state of Andhra Pradesh. Data on demographics, ocular and systemic history and risk factors were collected at both baseline and follow-up. Cataracts were classified into pure forms (nuclear, cortical, posterior subcapsular cataract (PSC)) and mixed cataract. Cataract types were defined using baseline assessment. Incidence of cataract surgery was defined as cataract surgery performed in either eye during the 15-year follow-up period among participants who did not have cataract surgery at baseline.Results In total, 2576 (47.7%) of 5395 participants aged 30 years and above at baseline were included, with a mean age of 42.9 years (SD±9.9) and 45% were men. The 15-year crude incidence risk of cataract surgery was 17.5% (95% CI 16.0% to 19.0%) and rate was 17.7 per 100 person-years (95% CI 17.3 to 18.1). In multivariable logistic regression, the incidence of cataract surgery was significantly higher among older adults (OR 11.09; 95% CI 6.92 to 17.78 in 60 years and above), participants with diabetes mellitus (OR 3.27; 95% CI 1.18 to 9.08), those with pure nuclear cataract (OR 2.27; 95% CI 1.56 to 3.30), pure cortical cataract (OR 3.22; 95% CI 1.79 to 5.79), pure PSC (OR 14.70; 95% CI 6.25 to 34.54) and mixed cataract (OR 6.60; 95% CI 4.13 to 10.55).Conclusions Our study found a significantly higher incidence rate of cataract surgery in rural south India. Targeted interventions are needed to enhance eye care services further and improve access to surgical care.
dlvr.it
December 3, 2025 at 5:43 PM
Ophthopedia Update: Impact of epiretinal membrane surgery on glaucoma progression: influence of glaucoma severity and internal limiting membrane peeling: Background

This retrospective, comparative study evaluated the long-term impact of pars plana vitrectomy… #Ophthalmology #Ophthotwitter #BJO
Impact of epiretinal membrane surgery on glaucoma progression: influence of glaucoma severity and internal limiting membrane peeling
Background This retrospective, comparative study evaluated the long-term impact of pars plana vitrectomy (PPV) for epiretinal membrane (ERM) removal on glaucoma progression, focusing on the influence of glaucoma severity and adjunctive internal limiting membrane (ILM) peeling.Methods A total of 231 eyes from patients diagnosed with primary open-angle glaucoma and coexisting ERM were included. Participants were divided into two groups: 114 eyes underwent PPV for ERM removal (PPV group) and 117 eyes did not undergo surgery (non-PPV group). The PPV group was further subdivided based on glaucoma severity and ILM peeling. Functional and structural parameters were assessed over 4 years using visual field testing, intraocular pressure (IOP) measurement, and optical coherence tomography. Linear mixed models were used for statistical analysis.Results The PPV group demonstrated a significant deterioration in mean deviation and visual field index, compared with the non-PPV group, over 4 years (p
dlvr.it
December 3, 2025 at 5:43 PM
Ophthopedia Update: Establishing non-inferiority margins in myopia management contact lens trials with an active control: The myopia control field stands at an ethical crossroads. Withholding proven soft contact lens interventions in control arms of myopia management trials is increasingly viewed…
Establishing non-inferiority margins in myopia management contact lens trials with an active control
The myopia control field stands at an ethical crossroads. Withholding proven soft contact lens interventions in control arms of myopia management trials is increasingly viewed as ethically questionable and operationally challenging, particularly given that MiSight 1-day contact lens has demonstrated efficacy in at least four randomised controlled trials. The recent methodological evolution towards non-inferiority trials against an established control rather than a placebo (single vision) is a welcome change. However, this shift raises a critical challenge: setting non-inferiority margins that are both clinically meaningful and statistically robust.
dlvr.it
December 3, 2025 at 5:14 PM
Ophthopedia Update: Epigenetic Age Could Be a Factor in Fast vs Slow Glaucoma Progression: Findings from this retrospective study indicate that accelerated epigenetic aging, as measured by DNA methylation patterns, could be linked to faster glaucoma progression. #Ophthalmology #News
Epigenetic Age Could Be a Factor in Fast vs Slow Glaucoma Progression
Findings from this retrospective study indicate that accelerated epigenetic aging, as measured by DNA methylation patterns, could be linked to faster glaucoma progression.
dlvr.it
December 3, 2025 at 4:57 PM
Ophthopedia Update: ChatGPT-Assisted Glaucoma Diagnosis: A Health-Equitable Multi-Ancestry Analysis using Visual Field and Optical Coherence Tomography Data: Early glaucoma detection is challenging due to variable ocular anatomy, non-glaucomatous optic… #Ophthalmology #Ophthotwitter #Scicomm
ChatGPT-Assisted Glaucoma Diagnosis: A Health-Equitable Multi-Ancestry Analysis using Visual Field and Optical Coherence Tomography Data
Early glaucoma detection is challenging due to variable ocular anatomy, non-glaucomatous optic neuropathy impacting optical coherence tomography (OCT) results, and the subjective nature of visual field (VF) tests. Multimodal large language models may overcome these challenges to provide equitable and accurate screening diagnoses across ancestries and glaucoma genetic predispositions. We evaluated ChatGPT o1 Pro’s accuracy in identifying glaucoma using circumpapillary retinal nerve fiber layer (RNFL) OCT and VF data, and its consistency across ancestries and glaucoma polygenic risk scores (PRS).
dlvr.it
December 3, 2025 at 4:20 PM
Ophthopedia Update: Cataract surgery necessary in patients with dementia: Age-related dementia, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy and hearing loss are all more common in the elderly patient.
The average age of onset of a cataract in the U.S. is about 60…
Cataract surgery necessary in patients with dementia
Age-related dementia, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy and hearing loss are all more common in the elderly patient. The average age of onset of a cataract in the U.S. is about 60 years and for cataract/IOL surgery, 74 years. The average age of onset for age-related dementia is 70 years, for glaucoma 55 years, for AMD 60 years, and for diabetic retinopathy in adult-onset diabetes 65 years. All of these age-related diseases tend to progress with increasing age. A patient who presents for cataract/IOL surgery in their 70s has a 10% to 15% chance of having
dlvr.it
December 3, 2025 at 2:29 PM
Ophthopedia Update: Cataract surgery necessary in patients with dementia: Age-related dementia, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy and hearing loss are all more common in the elderly patient.
The average age of onset of a… #ophthalmology #eye #eyenews
Cataract surgery necessary in patients with dementia
Age-related dementia, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy and hearing loss are all more common in the elderly patient. The average age of onset of a cataract in the U.S. is about 60 years and for cataract/IOL surgery, 74 years. The average age of onset for age-related dementia is 70 years, for glaucoma 55 years, for AMD 60 years, and for diabetic retinopathy in adult-onset diabetes 65 years. All of these age-related diseases tend to progress with increasing age. A patient who presents for cataract/IOL surgery in their 70s has a 10% to 15% chance of having
dlvr.it
December 3, 2025 at 2:29 PM
Ophthopedia Update: Visual intelligence, collaborative AI may advance health care: SAN DIEGO — Visual intelligence and collaborative AI approaches may advance health care, according to a keynote speaker at AIMed25.
“Our recent work focuses on making AI for health care more accurate, efficient and…
Visual intelligence, collaborative AI may advance health care
SAN DIEGO — Visual intelligence and collaborative AI approaches may advance health care, according to a keynote speaker at AIMed25. “Our recent work focuses on making AI for health care more accurate, efficient and deployable in real clinical settings,” Chen Chen, PhD, associate professor at the Center for Research in Computer Vision, the department of computer science and the Institute of Artificial Intelligence at the University of Central Florida, told Healio. Chen and colleagues have developed advanced medical image analysis models for tasks like tumor segmentation, pathology slide
dlvr.it
December 3, 2025 at 2:25 PM
Ophthopedia Update: Visual intelligence, collaborative AI may advance health care: SAN DIEGO — Visual intelligence and collaborative AI approaches may advance health care, according to a keynote speaker at AIMed25.
“Our recent work focuses on making AI for health care… #ophthalmology #eye #eyenews
Visual intelligence, collaborative AI may advance health care
SAN DIEGO — Visual intelligence and collaborative AI approaches may advance health care, according to a keynote speaker at AIMed25. “Our recent work focuses on making AI for health care more accurate, efficient and deployable in real clinical settings,” Chen Chen, PhD, associate professor at the Center for Research in Computer Vision, the department of computer science and the Institute of Artificial Intelligence at the University of Central Florida, told Healio. Chen and colleagues have developed advanced medical image analysis models for tasks like tumor segmentation, pathology slide
dlvr.it
December 3, 2025 at 2:25 PM
Ophthopedia Update: FDA veteran who recently took top post intends to retire: A longtime FDA official who took over last month as the agency’s top drug regulator intends to retire.
The departure of Richard Pazdur, MD — who spent nearly 3 decades with FDA and became founding director of its…
FDA veteran who recently took top post intends to retire
A longtime FDA official who took over last month as the agency’s top drug regulator intends to retire. The departure of Richard Pazdur, MD — who spent nearly 3 decades with FDA and became founding director of its Oncology Center of Excellence 8 years ago — comes a few weeks after he agreed to serve as director of the agency’s Center for Drug Evaluation and Research (CDER), which oversees most prescription drugs and over-the-counter medicines. “We respect Dr. Pazdur’s decision to retire and honor his 26 years of distinguished service at the FDA,” an FDA spokesperson said in a statement provided
dlvr.it
December 3, 2025 at 2:11 PM
Ophthopedia Update: FDA veteran who recently took top post intends to retire: A longtime FDA official who took over last month as the agency’s top drug regulator intends to retire.
The departure of Richard Pazdur, MD — who spent nearly 3 decades with FDA and became… #ophthalmology #eye #eyenews
FDA veteran who recently took top post intends to retire
A longtime FDA official who took over last month as the agency’s top drug regulator intends to retire. The departure of Richard Pazdur, MD — who spent nearly 3 decades with FDA and became founding director of its Oncology Center of Excellence 8 years ago — comes a few weeks after he agreed to serve as director of the agency’s Center for Drug Evaluation and Research (CDER), which oversees most prescription drugs and over-the-counter medicines. “We respect Dr. Pazdur’s decision to retire and honor his 26 years of distinguished service at the FDA,” an FDA spokesperson said in a statement provided
dlvr.it
December 3, 2025 at 1:49 PM
Ophthopedia Update: Retinal pigment epithelium disruption lesions on optical coherence tomography in patients with vitreoretinal lymphoma: Vitreoretinal lymphoma (VRL) is a subtype of central nervous system (CNS) lymphoma (CNSL), most commonly presenting as… #Ophthalmology #Ophthotwitter #Scicomm
Retinal pigment epithelium disruption lesions on optical coherence tomography in patients with vitreoretinal lymphoma
Vitreoretinal lymphoma (VRL) is a subtype of central nervous system (CNS) lymphoma (CNSL), most commonly presenting as diffuse large B-cell non-Hodgkin’s lymphoma.1,2 It is highly malignant that often presents bilaterally and has vision- and life-threatening consequences.
dlvr.it
December 3, 2025 at 1:20 PM
Ophthopedia Update: The Effect of Age on Wound Healing in the Laser Induced Choroidal Neovascularization Model: Publication date: Available online 3 December 2025

Source: Experimental Eye Research

Author(s): William F. Horrigan, Quinn Caron, Aidan Rodriguez, Rupesh Singh, Bela Anand-Apte
The Effect of Age on Wound Healing in the Laser Induced Choroidal Neovascularization Model
Publication date: Available online 3 December 2025 Source: Experimental Eye Research Author(s): William F. Horrigan, Quinn Caron, Aidan Rodriguez, Rupesh Singh, Bela Anand-Apte
dlvr.it
December 3, 2025 at 10:22 AM
Ophthopedia Update: Isolated Haab Striae Point to a Pressured Past: Figure Legend: #Ophthalmology #Ophthotwitter #Scicomm
Isolated Haab Striae Point to a Pressured Past
Figure Legend:
dlvr.it
December 3, 2025 at 10:21 AM
Ophthopedia Update: Tele-eye care in Nigeria: interpreting acceptance through an equity and policy lens: Publication date: Available online 2 December 2025

Source: AJO International

Author(s): Abha Gahlot, Sushma Narsing Katkuri, Janvi Patel, Jeffrin Reneus Paul #Ophthalmology #AJOInternational
Tele-eye care in Nigeria: interpreting acceptance through an equity and policy lens
Publication date: Available online 2 December 2025 Source: AJO International Author(s): Abha Gahlot, Sushma Narsing Katkuri, Janvi Patel, Jeffrin Reneus Paul
dlvr.it
December 3, 2025 at 9:59 AM
ICYMI: Ophthopedia Update: Optimizing Glaucoma Care in Ghana: A Mixed-Methods Study of Optometrists' Practices, Challenges, and Capacity Needs: Publication date: Available online 30 November 2025

Source: AJO International

Author(s): Irene Nkansa-Kyeremateng,… #Ophthalmology #AJOInternational
Optimizing Glaucoma Care in Ghana: A Mixed-Methods Study of Optometrists' Practices, Challenges, and Capacity Needs
Publication date: Available online 30 November 2025 Source: AJO International Author(s): Irene Nkansa-Kyeremateng, Albert Kwadjo Amoah Andoh, Eldrick Adu Acquah, Isaiah Osei Duah Junior, Beatrice Okrah, Kwadwo Owusu Akuffo
dlvr.it
December 3, 2025 at 9:53 AM
Ophthopedia Update: Comment on: Surgical Outcomes of Lens Removal with or without Intraocular Lens Implantation in Marfan Syndrome: A Retrospective Cohort Study [Letter] #Ophthomology #Eye #Ophthotwitter
Letter for the article Surgical Outcomes of Lens Removal with or Witho | OPTH
Letter for the article Surgical Outcomes of Lens Removal with or Without Intraocular Lens Implantation in Marfan Syndrome: A Retrospective Cohort Study
dlvr.it
December 3, 2025 at 8:59 AM
Ophthopedia Update: Comparison of Amniotic Membrane Extract and Insulin Eye Drops for the Management of Persistent Epithelial Defects: A Multicenter Retrospective Study #Ophthomology #Eye #Ophthotwitter
Topical Insulin Versus Amniotic Membrane Extract Eye Drops for Refract | OPTH
To compare the efficacy and safety of topical insulin and AMEED in promoting healing of corneal PEDs refractory to conventional therapy.
dlvr.it
December 3, 2025 at 8:50 AM
Ophthopedia Update: Clinical Outcomes of Selective Laser Trabeculoplasty in Thai Glaucoma Patients Across Initial, Adjunctive, and Replacement Therapy #Ophthomology #Eye #Ophthotwitter
Clinical Outcomes of Selective Laser Trabeculoplasty in Thai Glaucoma | OPTH
The outcomes of selective laser trabeculoplasty (SLT) in Thai glaucoma patients across three treatment groups–initial, adjunctive, and replacement therapy.
dlvr.it
December 3, 2025 at 7:52 AM